CD19 chimeric antigen receptor-T (CAR-T) cell therapy has achieved remarkable results in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The gene discussed is CD19; the disease is B-cell acute lymphoblastic leukemia.